CASI(US:CASI) Jin Rong Jie·2025-07-29 14:03Group 1 - The core viewpoint of the article highlights the significant increase in revenue for CASI Pharmaceuticals, with a total revenue of $6.24 million for the fiscal year ending March 31, 2025, representing an 83.04% year-over-year growth [1][2] - CASI Pharmaceuticals reported a net loss of $10.75 million, which is a 12.83% decrease compared to the previous year [1] - The company's stock opened at $1.77 per share, reflecting a 9.26% increase, with a total market capitalization of $27.42 million [1] Group 2 - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, focused on providing advanced treatment solutions for blood cancers in China [2] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [2] - CASI's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2]